Bibliography

Text Books


Journal/Book Section Editor


Books for General Readership

Monographs


Over 60,000 copies have been distributed free of charge to health care workers in the developing world countries by the end of 2008.

Papers


*RPW bibl*


RPW bibl


RPW bibl


RPW bibl


*RPW bibl*


RPW bibl


453. Wenzel, RP. Introduction to antifungal prophylaxis in the surgical intensive care unit. (in press)


Abstracts/Letters to the Editor


RPW bibl


44. Stillman RI, Donowitz LG, Wenzel RP. The emergence of *Staphylococcus epidermidis* as a hospital wide nosocomial bloodstream pathogen. 23rd Interscience Conference on Antimicrobial agents and Chemotherapy, Las Vegas, Nevada, October 24-26, 1983.


*RPW bibl*


203. Wenzel RP. Why Does Therapy Fail (Or Appear to Succeed)? 42nd ICAAC Abstracts; #38(L,K)-413, p.450, 2002.


**RESEARCH SUPPORT SUMMARY**

**University of Virginia** 1972-1986

<table>
<thead>
<tr>
<th>Sponsor</th>
<th># Years of Funding:</th>
<th>Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
<td>1974-78</td>
<td>Study of the Efficacy of an OSU-1 Mycoplasma pneumoniae Vaccine in Marine Corps Recruits</td>
</tr>
<tr>
<td>Centers for Disease Control</td>
<td>1974-78</td>
<td>Development of a Statewide Program for Surveillance/Control of Nosocomial Infections</td>
</tr>
<tr>
<td>State of Virginia</td>
<td>1978-84</td>
<td>Continuation of CDC Project to Develop Statewide Program for Surveillance and Control of Nosocomial Infections</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>1985-86</td>
<td>Analysis of Attributable Mortality Data in Nosocomial Pneumonia - Fogerty Award</td>
</tr>
</tbody>
</table>

**University of Iowa** 1986-1995

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Period</th>
<th>Project</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutter Biological</td>
<td>3/87-3/88</td>
<td>Efficacy of Pseudomonas Immune Globulin in the Treatment of <em>P. aeruginosa</em> Bacteremia in Compromised Patients</td>
<td>$5,000</td>
</tr>
<tr>
<td>Xoma Corporation</td>
<td>3/87-4/89</td>
<td>Efficacy of Anti-Endotoxin Antibody in the Treatment of Suspected Gram-Negative Sepsis</td>
<td>$94,800</td>
</tr>
<tr>
<td>Company</td>
<td>Study Period</td>
<td>Summary</td>
<td>Costs</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Glaxo, Inc.</td>
<td>8/87-8/88</td>
<td>Comparison of Cefzolin to Cefuroxime in Cardiac Surgery</td>
<td>$10,000</td>
</tr>
<tr>
<td>Roerig/Pfizer</td>
<td>8/87-12/88</td>
<td>In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates to new Antibiotics</td>
<td>$18,095</td>
</tr>
<tr>
<td>Hoechst-Roussel Pharmaceuticals</td>
<td>1/88-7/88</td>
<td>Effects of Protein Binding on In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates</td>
<td>$22,000</td>
</tr>
<tr>
<td>Lederle Laboratories</td>
<td>8/88-7/89</td>
<td>Comparison of Beta-Lactam Antibiotics Plus Gentamycin-Bloodstream Isolates</td>
<td>$8,500</td>
</tr>
<tr>
<td>Calgon Vestal Laboratories</td>
<td>7/87-6/90</td>
<td>Efficacy Study of Handwashing Agents: Calstat vs. Hibiclens</td>
<td>$68,000</td>
</tr>
<tr>
<td>ER Squibb and Sons</td>
<td>8/87-7/89</td>
<td>Attributable Mortality of Hospital</td>
<td>$20,000</td>
</tr>
<tr>
<td>Hoechst-Roussel Pharmaceuticals</td>
<td>6/90-5/91</td>
<td>Use of Pentoxifylline (Trental) in Patients with Amphetersin B Induced Renal Toxicity - Pilot Study</td>
<td>$11,500</td>
</tr>
<tr>
<td>Lilly Laboratories</td>
<td>11/89-11/90</td>
<td>Cilofungin in Disseminated Candidiasis: Dose Ranging Study</td>
<td>$21,605</td>
</tr>
<tr>
<td>Fujisawa SmithKline Corporation</td>
<td>1/90-12/90</td>
<td>In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates to New Antibiotics</td>
<td>$9,750</td>
</tr>
<tr>
<td>Hoechst-Roussel Pharmaceuticals</td>
<td>6/90-5/91</td>
<td>Use of Pentoxifylline (Trental) in Patients with Amphetersin B Induced Renal Toxicity - Pilot Study</td>
<td>$11,500</td>
</tr>
<tr>
<td>Pharmaco/Synergen</td>
<td>4/91-8/92</td>
<td>Human Recombinant Interleukin-1 Receptor Antagonist (IL-Irs) in the Treatment of Sepsis Syndrome</td>
<td>$35,936</td>
</tr>
<tr>
<td>Cutter (Miles)</td>
<td>4/91-1/93</td>
<td>Prospective, Double-Blind, Controlled, Randomized, Multi-Center Study of the Safety and Efficacy of TNF MAb for the Treatment of</td>
<td>$237,800</td>
</tr>
</tbody>
</table>
Patients with Sepsis Syndrome

Kimberly Clark  8/91-1/92 Sterile Wrap Events Study (Pilot Phase)  $20,460

Pharmaco/  7/92-6/93 A Study to Evaluate the Safety and  $41,850
Synergen  Efficacy of Human Recombination Interleukin-1 Receptor Antagonist (IL-IRA) in the Treatment of Sepsis Syndrome

Pfizer Roerig  7/92-6/94 Epidemiology of the SIRS (Sepsis Syndrome)  $352,110

Kimberly Clark  7/92-2/93 Sterile Wrap Study  $62,200

Pact  7/93-6/94 Randomized, Placebo-Controlled Trial of E5 Monoclonal Antibody in Patients with Severe Sepsis  $41,250

Kimberly Clark  8/93-6/94 Sterile Wrap Events Study  $45,000

National Institutes of Health  9/91-8/96 Research Training Grant in Hospital Epidemiology (T-32)  $399,241

Merck  12/93-11/95 Multicenter Study to Compare the Safety, Tolerability and Immunogenicity of Three Consistency Lots of VAQTA in Healthy Adults  $47,500

Miles  5/94-2/95 Prospective, Double-Blind, Randomized, Multicenter North American Study of the Safety and Efficacy of TNF MAb for the Treatment of Patients with Septic Shock  $131,885

Hoffman-LaRoche  4/94-6/95 Phase II, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of Ro 45-2081 in the Treatment of Severe Sepsis/Septic Shock  $47,250

Abbott  9/94-9/95 Achievement Awards Outcomes Research  $50,000

Lederle Laboratories  9/94-9/95 SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance  $208,620

SmithKline-Beecham  9/94-9/95 A Randomized Placebo-Controlled, Double-Blind Comparative Study of Intranasal Mupirocin Ointment for Preventing S aureus Surgical Wound Infections  $453,750

1995 - Medical College of Virginia/Virginia Commonwealth University (PI in all but one)
<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Period</th>
<th>Project</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lederle Laboratories</td>
<td>9/95-12/96</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
<td>$150,000</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>1995-2001</td>
<td>A Multi-Center Study of the Risk Factors and Outcome of Candida Bloodstream Infections in Surgical ICUs.</td>
<td>$497,284</td>
</tr>
<tr>
<td>Rhone-Poulenc</td>
<td>1997-2001</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
<td>$205,000</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>1997-2002</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
<td>$790,000</td>
</tr>
<tr>
<td>Proctor and Gamble</td>
<td>1997-1998</td>
<td>Handwashing and Predictors of Compliance</td>
<td>$74,000</td>
</tr>
<tr>
<td>Rhone-Poulenc</td>
<td>1998</td>
<td>Educational Conference - SCOPE</td>
<td>$250,000</td>
</tr>
<tr>
<td>Merck</td>
<td>1999-2002</td>
<td>SCOPE: Pharmacy Component</td>
<td>$300,000</td>
</tr>
<tr>
<td>Intrabiotics</td>
<td>1998-2000</td>
<td>Ramoplanin for VRE GI decolonization</td>
<td>$85,000</td>
</tr>
<tr>
<td>Pharmacia and Upjohn</td>
<td>2000-2002</td>
<td>Antibiotic resistance in the community</td>
<td>$400,000</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2002-2003</td>
<td>SCOPE</td>
<td>$200,000</td>
</tr>
<tr>
<td>Cubist</td>
<td>2003</td>
<td>SCOPE</td>
<td>$5,000</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2003-2006</td>
<td>SCOPE</td>
<td>$200,000</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2006-2007</td>
<td>Epidemiology of CA-MRSA in families (G. Bearman – PI)</td>
<td>$198,000</td>
</tr>
<tr>
<td>Gates Foundation</td>
<td>2007-2008</td>
<td>Educational award to invite 50 women from developing countries to attend the International Society for Infectious Diseases Congress in Kuala-Lampur – June 2008 (RP Wenzel – PI)</td>
<td>$250,000</td>
</tr>
</tbody>
</table>